Lv2
110 积分 2025-09-02 加入
Neoadjuvant chemo-immunotherapy following concurrent immuno-chemoradiotherapy and immune-maintenance therapy as primary treatment for locally advanced cervical cancer: A prospective, single-arm, phase 2 trial
24天前
已关闭
High versus low dose irradiation for tumor immune reprogramming
1个月前
已完结
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
2个月前
已完结
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?
2个月前
已完结
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
2个月前
已完结
The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial
2个月前
已完结
Immunotherapy plus chemoradiotherapy in cervical cancer management
2个月前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2个月前
已完结
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2个月前
已完结
Immunotherapy plus chemoradiotherapy in cervical cancer management
2个月前
已完结
皖公网安备34019202002308
